Acadian Asset Management’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History

Acadian Asset Management’s Portfolio BSPM Stock Details BSPM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-107,196	Closed	-$239K	–	1897
2018 Q2	$239K	Buy	107,196 +6,001	+6%	+$15K	﹤0.01%	1039
2018 Q1	$331K	Buy	101,195 +85,628	+550%	+$271K	﹤0.01%	951
2017 Q4	$28K	Buy	15,567 +6,669	+75%	+$11.8K	﹤0.01%	1326
2017 Q3	$11K	Sell	8,898 -2,566	-22%	-$3.57K	﹤0.01%	1270
2017 Q2	$18K	Buy	11,464 +3,548	+45%	+$6.17K	﹤0.01%	1276
2017 Q1	$18K	Buy	7,916 +3,719	+89%	+$9.77K	﹤0.01%	1391
2016 Q4	$12K	Hold	4,197	–	–	﹤0.01%	1409
2016 Q3	$16K	Buy	+4,197	New	+$15.3K	﹤0.01%	1182

Acadian Asset Management's BSPM Position: Q3 2018 in Review

Acadian Asset Management sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q3 2018, closing a stake of 107,196 shares — an estimated $239K sold.

Acadian Asset Management first reported a position in BSPM in Q3 2016 and held it in 8 quarters. The position peaked at $331K in Q1 2018. 0 funds tracked by Wall St. Rank hold BSPM as of Q3 2018.

Acadian Asset Management reported no remaining Biostar Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Acadian Asset Management sold 107,196 Biostar Pharmaceuticals, Inc. shares in Q3 2018, an estimated $239K.
Acadian Asset Management first reported a position in Biostar Pharmaceuticals, Inc. in Q3 2016 and held it in 8 quarters.
Acadian Asset Management's Biostar Pharmaceuticals, Inc. position peaked at $331K in Q1 2018.
0 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q3 2018.

Based on Acadian Asset Management's 13F filing for Q3 2018, filed 30 Oct 2018.